跳至主要内容
临床试验/NCT05774990
NCT05774990已完成不适用

Incidence and Risk Factors for Invasive Mold Infections in Children During First-Line Chemotherapy for Primary Acute Leukemia: Protocol for a National Retrospective Cohort Study

University of Southern Denmark2 个研究点 分布在 1 个国家目标入组 621 人开始时间: 2023年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
621
试验地点
2
主要终点
Mortality form invasive mold infection in childhood AML and ALL in Denmark.

研究概览

简要总结

The study aims to evaluate the occurrence, mortality, and risk factors for invasive mold infections (IMI) in children treated with chemotherapy for acute leukemia in Denmark. The study will be a retrospective nationwide survey study of all children who received first-line chemotherapy for acute leukemia from 2008 to 2022 in Danish pediatric oncology units. The study population includes 621 children under the age of 18. Data will be collected from medical records, hospital databases, and national databases. When the IMI subgroup has been identified, this will be compared to the leukemic group that did not develop IMI. Statistical analysis can then determine the occurrence, mortality rate, and possible IMI risk factors.

详细描述

Chemotherapy can weaken children's immune system, making them vulnerable to infections, including invasive mold infections (IMI), caused mainly by Aspergillus spp. The at-risk population for IMI in children with acquired immunodeficiency is patients with prolonged granulocytopenia due to hematologic malignancies treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT) recipients and children receiving long-term corticosteroid treatment. Incidences and mortality rates are often reported as high.

In a retrospective cohort study, we aim to obtain an epidemiological overview of IMI in children receiving first-line treatment for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) in Denmark from 2008 to 2022 and identify possible risk factors, including treatment-related adverse effects.

Objectives

  1. To determine and compare the incidence of IMI in childhood AML and ALL during first-line chemotherapy in Denmark.
  2. To determine and compare the mortality of IMI in childhood AML and ALL during first-line chemotherapy in Denmark.
  3. To explore risk factors for IMI in childhood AML and ALL during first-line chemotherapy in Denmark.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
— 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Age <18 years at the time of inclusion
  • Received first-line treatment for ALL or AML
  • Treatment at a Danish tertiary pediatric oncology unit (Rigshospitalet, Aarhus University Hospital, Odense University Hospital, and Aalborg University Hospital)
  • Treatment initiation January 1st, 2008, to December 31st, 2022

排除标准

  • Not meeting inclusion criteria

结局指标

主要结局

Mortality form invasive mold infection in childhood AML and ALL in Denmark.

时间窗: Up to three years

The number of subjects in the cohort dying from an invasive mold infection during their leukemia treatment period

Incidence of invasive mold infection in childhood AML and ALL in Denmark

时间窗: Up to three years

The number of subjects in the cohort infected with an invasive mold during leukemia treatment period as defined by the European Organization for Research and Treatment of Cancer Mycoses study group (EORTC/MSG) criteria

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验